DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner

Journal of Neuroimmunology

Volumn 283, Issue , 2015, Pages 74-85

  Gillard, Geoffrey O ^a   Collette, Brian ^a   Anderson, John ^a   Chao, Jianhua ^a   Scannevin, Robert H ^a   Huss, David J ^a   Fontenot, Jason D ^a  

^a BIOGEN   (United States)

Author keywords

Cytokine; Dimethyl fumarate (DMF); Monoethyl fumarate (MEF); Monomethyl fumarate (MMF); Nuclear factor (erythroid derived 2) like 2 (Nrf2); Nuclear factor kappa light chain enhancer of activated B cells (NF B)

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID ETHYL ESTER; FUMARIC ACID METHYL ESTER; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROTEIN P52; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR NRF2; CATION; CITRACONIC ACID; CYTOKINE; ETHYL FUMARATE; FUMARIC ACID DERIVATIVE; MALEIC ACID DERIVATIVE; NFE2L2 PROTEIN, MOUSE; RELA PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA; TUMOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE TUMOR; BURKITT LYMPHOMA; CELL CULTURE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; KNOCKOUT MOUSE; LYMPHOCYTE; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); SPLEEN; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BONE NEOPLASMS; BURKITT LYMPHOMA; CATIONS; CELL LINE, TUMOR; CELLS, CULTURED; CYTOKINES; FUMARATES; HUMANS; IN VITRO TECHNIQUES; LYMPHOCYTES; MALEATES; MICE; MICE, KNOCKOUT; MOLECULAR STRUCTURE; NEOPLASM PROTEINS; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NF-KAPPA B P52 SUBUNIT; OSTEOSARCOMA; SIGNAL TRANSDUCTION; SPLEEN; TRANSCRIPTION FACTOR RELA;

EID: 84929574626     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.04.006     Document Type: Article

References (73)

1. Albrecht P., Bouchachia I., Goebels N., Henke N., Hofstetter H.H., Issberner A., Kovacs Z., Lewerenz J., Lisak D., Maher P., et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J. Neuroinflammation 2012, 9:163.
2. Berg E.L., Kunkel E.J., Hytopoulos E., Plavec I. Characterization of compound mechanisms and secondary activities by BioMAP analysis. J. Pharmacol. Toxicol. Methods 2006, 53:67-74.
3. Berg E.L., Yang J., Melrose J., Nguyen D., Privat S., Rosler E., Kunkel E.J., Ekins S. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J. Pharmacol. Toxicol. Methods 2010, 61:3-15.
4. Chen H., Assmann J.C., Krenz A., Rahman M., Grimm M., Karsten C.M., Kohl J., Offermanns S., Wettschureck N., Schwaninger M. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J. Clin. Invest. 2014, 124:2188-2192.
5. Cross S.A., Cook D.R., Chi A.W., Vance P.J., Kolson L.L., Wong B.J., Jordan-Sciutto K.L., Kolson D.L. Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection. J. Immunol. 2011, 187:5015-5025.
6. Cuadrado A., Martin-Moldes Z., Ye J., Lastres-Becker I. Transcription factors NRF2 and NF-kappaB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation. J. Biol. Chem. 2014, 289:15244-15258.
7. Dibbert S., Clement B., Skak-Nielsen T., Mrowietz U., Rostami-Yazdi M. Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism. Arch. Dermatol. Res. 2013, 305:447-451.
8. Digby J.E., Martinez F., Jefferson A., Ruparelia N., Chai J., Wamil M., Greaves D.R., Choudhury R.P. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler. Thromb. Vasc. Biol. 2012, 32:669-676.
9. Fox R. The New England Journal of Medicine publishes pivotal data demonstrating efficacy and safety of oral BG-12 (dimethyl fumarate) in multiple sclerosis. Can. J. Neurosci. Nurs. 2012, 34:7-11.
10. Fox R.J., Miller D.H., Phillips J.T., Hutchinson M., Havrdova E., Kita M., Yang M., Raghupathi K., Novas M., Sweetser M.T., Viglietta V., Dawson K.T. CONFIRM Study Investigators, Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 2012, 367(12):1087-1097.
11. Fox R.J., Kita M., Cohan S.L., Henson L.J., Zambrano J., Scannevin R.H., O'Gorman J., Novas M., Dawson K.T., Phillips J.T. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr. Med. Res. Opin. 2014, 30:251-262.
12. Garcia-Pineres A.J., Lindenmeyer M.T., Merfort I. Role of cysteine residues of p65/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci. 2004, 75:841-856.
13. Gerdes S., Shakery K., Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br. J. Dermatol. 2007, 156:838-842.
14. Ghashghaeinia M., Bobbala D., Wieder T., Koka S., Bruck J., Fehrenbacher B., Rocken M., Schaller M., Lang F., Ghoreschi K. Targeting glutathione by dimethylfumarate protects against experimental malaria by enhancing erythrocyte cell membrane scrambling. Am. J. Physiol. Cell Physiol. 2010, 299:C791-C804.
15. Ghoreschi K., Bruck J., Kellerer C., Deng C., Peng H., Rothfuss O., Hussain R.Z., Gocke A.R., Respa A., Glocova I., et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med. 2011, 208:2291-2303.
16. Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 2011, 25:37-52.
17. Gold R., Kappos L., Arnold D.L., Bar-Or A., Giovannoni G., Selmaj K., Tornatore C., Sweetser M.T., Yang M., Sheikh S.I., Dawson K.T. DEFINE Study Investigators, Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012, 367(12):1098-1107.
18. Gold R., Linker R.A., Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin. Immunol. 2012, 142:44-48.
19. Hanson J., Gille A., Zwykiel S., Lukasova M., Clausen B.E., Ahmed K., Tunaru S., Wirth A., Offermanns S. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J. Clin. Invest. 2010, 120:2910-2919.
20. Hanson J., Gille A., Offermanns S. Role of HCA(2) (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacol. Ther. 2012, 136:1-7.
21. Hoefnagel J.J., Thio H.B., Willemze R., Bouwes Bavinck J.N. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br. J. Dermatol. 2003, 149:363-369.
22. Kappos L., Gold R., Miller D.H., Macmanus D.G., Havrdova E., Limmroth V., Polman C.H., Schmierer K., Yousry T.A., Yang M., et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 372:1463-1472.
23. Kappos L., Gold R., Miller D.H., MacManus D.G., Havrdova E., Limmroth V., Polman C.H., Schmierer K., Yousry T.A., Eraksoy M., et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult. Scler. 2012, 18:314-321.
24. Kawai T., Akira S. TLR signaling. Cell Death Differ. 2006, 13:816-825.
25. Kim J.E., You D.J., Lee C., Ahn C., Seong J.Y., Hwang J.I. Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. Cell. Signal. 2010, 22:1645-1654.
26. Kunkel E.J., Dea M., Ebens A., Hytopoulos E., Melrose J., Nguyen D., Ota K.S., Plavec I., Wang Y., Watson S.R., et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J. 2004, 18:1279-1281.
27. Kunkel E.J., Plavec I., Nguyen D., Melrose J., Rosler E.S., Kao L.T., Wang Y., Hytopoulos E., Bishop A.C., Bateman R., et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev. Technol. 2004, 2:431-441.
28. Kwok B.H., Koh B., Ndubuisi M.I., Elofsson M., Crews C.M. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem. Biol. 2001, 8:759-766.
29. Lee D.F., Kuo H.P., Liu M., Chou C.K., Xia W., Du Y., Shen J., Chen C.T., Huo L., Hsu M.C., et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol. Cell 2009, 36:131-140.
30. Lehmann J.C., Listopad J.J., Rentzsch C.U., Igney F.H., von Bonin A., Hennekes H.H., Asadullah K., Docke W.D. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J. Invest. Dermatol. 2007, 127:835-845.
31. Linker R.A., Gold R. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Curr. Neurol. Neurosci. Rep. 2013, 13:394.
32. Linker R.A., Lee D.H., Stangel M., Gold R. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert. Rev. Neurother. 2008, 8:1683-1690.
33. Linker R.A., Lee D.H., Ryan S., van Dam A.M., Conrad R., Bista P., Zeng W., Hronowsky X., Buko A., Chollate S., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
34. Litjens N.H., Burggraaf J., van Strijen E., van Gulpen C., Mattie H., Schoemaker R.C., van Dissel J.T., Thio H.B., Nibbering P.H. Pharmacokinetics of oral fumarates in healthy subjects. Br. J. Clin. Pharmacol. 2004, 58:429-432.
35. Litjens N.H., Rademaker M., Ravensbergen B., Rea D., van der Plas M.J., Thio B., Walding A., van Dissel J.T., Nibbering P.H. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur. J. Immunol. 2004, 34:565-575.
36. Litjens N.H., van Strijen E., van Gulpen C., Mattie H., van Dissel J.T., Thio H.B., Nibbering P.H. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol. 2004, 4:22.
37. Litjens N.H., Rademaker M., Ravensbergen B., Thio H.B., van Dissel J.T., Nibbering P.H. Effects of monomethylfumarate on dendritic cell differentiation. Br. J. Dermatol. 2006, 154:211-217.
38. Loewe R., Pillinger M., de Martin R., Mrowietz U., Groger M., Holnthoner W., Wolff K., Wiegrebe W., Jirovsky D., Petzelbauer P. Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner. J. Invest. Dermatol. 2001, 117:1363-1368.
39. Loewe R., Holnthoner W., Groger M., Pillinger M., Gruber F., Mechtcheriakova D., Hofer E., Wolff K., Petzelbauer P. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J. Immunol. 2002, 168:4781-4787.
40. Lv P., Xue P., Dong J., Peng H., Clewell R., Wang A., Wang Y., Peng S., Qu W., Zhang Q., et al. Keap1 silencing boosts lipopolysaccharide-induced transcription of interleukin 6 via activation of nuclear factor kappaB in macrophages. Toxicol. Appl. Pharmacol. 2013, 272:697-702.
41. MacManus D.G., Miller D.H., Kappos L., Gold R., Havrdova E., Limmroth V., Polman C.H., Schmierer K., Yousry T.A., Eraksoy M., et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J. Neurol. 2011, 258:449-456.
42. Moed H., Stoof T.J., Boorsma D.M., von Blomberg B.M., Gibbs S., Bruynzeel D.P., Scheper R.J., Rustemeyer T. Identification of anti-inflammatory drugs according to their capacity to suppress type-1 and type-2T cell profiles. Clin. Exp. Allergy 2004, 34:1868-1875.
43. Moharregh-Khiabani D., Linker R.A., Gold R., Stangel M. Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr. Neuropharmacol. 2009, 7:60-64.
44. Mrowietz U., Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol. Med. 2005, 11:43-48.
45. Murphy T.H., Yu J., Ng R., Johnson D.A., Shen H., Honey C.R., Johnson J.A. Preferential expression of antioxidant response element mediated gene expression in astrocytes. J. Neurochem. 2001, 76:1670-1678.
46. Nelson K.C., Carlson J.L., Newman M.L., Sternberg P., Jones D.P., Kavanagh T.J., Diaz D., Cai J., Wu M. Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 1999, 40:1927-1935.
47. Nguyen T., Nioi P., Pickett C.B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 2009, 284:13291-13295.
48. Peng H., Guerau-de-Arellano M., Mehta V.B., Yang Y., Huss D.J., Papenfuss T.L., Lovett-Racke A.E., Racke M.K. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J. Biol. Chem. 2012, 287:28017-28026.
49. Peterson J.D., Herzenberg L.A., Vasquez K., Waltenbaugh C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3071-3076.
50. Pierce J.W., Schoenleber R., Jesmok G., Best J., Moore S.A., Collins T., Gerritsen M.E. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 1997, 272:21096-21103.
51. Rahman M., Muhammad S., Khan M.A., Chen H., Ridder D.A., Muller-Fielitz H., Pokorna B., Vollbrandt T., Stolting I., Nadrowitz R., et al. The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat. Commun. 2014, 5:3944.
52. Razani B., Reichardt A.D., Cheng G. Non-canonical NF-kappaB signaling activation and regulation: principles and perspectives. Immunol. Rev. 2011, 244:44-54.
53. Reick C., Ellrichmann G., Thone J., Scannevin R.H., Saft C., Linker R.A., Gold R. Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation. Exp. Neurol. 2014, 257:50-56.
54. Roll A., Reich K., Boer A. Use of fumaric acid esters in psoriasis. Indian J. Dermatol. Venereol. Leprol. 2007, 73:133-137.
55. Rostami Yazdi M., Mrowietz U. Fumaric acid esters. Clin. Dermatol. 2008, 26:522-526.
56. Rostami-Yazdi M., Clement B., Schmidt T.J., Schinor D., Mrowietz U. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J. Invest. Dermatol. 2009, 129:231-234.
57. Rostami-Yazdi M., Clement B., Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch. Dermatol. Res. 2010, 302:531-538.
58. Scannevin R.H., Chollate S., Jung M.Y., Shackett M., Patel H., Bista P., Zeng W., Ryan S., Yamamoto M., Lukashev M., Rhodes K.J. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. 2012, 341:274-284.
59. Schilling S., Goelz S., Linker R., Luehder F., Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 2006, 145:101-107.
60. Schmidt M.M., Dringen R. Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem. Int. 2010, 57:460-467.
61. Schmidt T.J., Ak M., Mrowietz U. Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-l-cysteine-preparation of S-substituted thiosuccinic acid esters. Bioorg. Med. Chem. 2007, 15:333-342.
62. Sheikh S.I., Nestorov I., Russell H., O'Gorman J., Huang R., Milne G.L., Scannevin R.H., Novas M., Dawson K.T. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin. Ther. 2013, 35:1582-1594. (e1589).
63. Shih V.F., Tsui R., Caldwell A., Hoffmann A. A single NFkappaB system for both canonical and non-canonical signaling. Cell Res. 2011, 21:86-102.
64. Spencer S.R., Wilczak C.A., Talalay P. Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. Cancer Res. 1990, 50:7871-7875.
65. Stoof T.J., Flier J., Sampat S., Nieboer C., Tensen C.P., Boorsma D.M. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br. J. Dermatol. 2001, 144:1114-1120.
66. Sun S.C. The noncanonical NF-kappaB pathway. Immunol. Rev. 2012, 246:125-140.
67. Swinney D.C., Xu Y.Z., Scarafia L.E., Lee I., Mak A.Y., Gan Q.F., Ramesha C.S., Mulkins M.A., Dunn J., So O.Y., et al. A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats. J. Biol. Chem. 2002, 277:23573-23581.
68. Tang H., Lu J.Y., Zheng X., Yang Y., Reagan J.D. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem. Biophys. Res. Commun. 2008, 375:562-565.
69. Vandermeeren M., Janssens S., Borgers M., Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 1997, 234:19-23.
70. Vandermeeren M., Janssens S., Wouters H., Borghmans I., Borgers M., Beyaert R., Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. J. Invest. Dermatol. 2001, 116:124-130.
71. Werdenberg D., Joshi R., Wolffram S., Merkle H.P., Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm. Drug Dispos. 2003, 24:259-273.
72. Wilms H., Sievers J., Rickert U., Rostami-Yazdi M., Mrowietz U., Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J. Neuroinflammation 2010, 7:30.
73. Yu M., Li H., Liu Q., Liu F., Tang L., Li C., Yuan Y., Zhan Y., Xu W., Li W., et al. Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway. Cell. Signal. 2011, 23:883-892.